COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department (NCT04356560) | Clinical Trial Compass
CompletedNot Applicable
COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department
Denmark100 participantsStarted 2020-03-23
Plain-language summary
Doctors, nurses and staff members of ear-nose and throat (ENT) departments are at high risk due to aerosol-inducing diagnostic procedures and surgery during the COVID-19 epidemic. Reports from China, Spain, Italy and England report of fatal cases among ENT specialists. With a concurrent lack of personal protection, it is of paramount importance to identify patients and healthcare workers at an early stage to prevent a COVID-19 outbreak in the department. A baseline study of all healthcare workers has been performed. Follow-up will be accomplished by interval testing, antibody measurements and REDcap Covid-19 questionnaires. All patients at risk of carrying SARS-CoV-2, or who are candidates for high-risk airway surgery will be tested. Infection control measures at the department will be implemented progressively according to the real-time surveillance results from both patients and healthcare workers.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Healthcare workers of all professions with daily routines at the Department of Otorhinolaryngology Head and Neck Surgery \& Audiology, Rigshospitalet University Hospital of Copenhagen
. All patients with symptoms of upper respiratory tract infections
. All patients undergoing surgery involving the mucosa of the upper airways
Exclusion criteria
. healthcare workers not affiliated to the department
. Patients without symptoms of upper respiratory tract infection (e.g otitis externa, fractures)
. Patients undergoing surgery not involving the upper airway (e.g thyroidectomy, Neck)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of healthcare workers with SARS-CoV-2
Timeframe: 6 months
2
Incidence of ENT patients with SARS-CoV-2
Timeframe: 6 months
3
Development of SARS-CoV-2 antibodies among healthcare workers